Case Report
Acute Coronary Syndromes Complicating the First Infusion of Rituximab

https://doi.org/10.3816/CLM.2008.n.035Get rights and content

Abstract

The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions. We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab. All 3 patients received rituximab according to a standardized institutional rate schedule, and all received pre-medication with acetaminophen and diphenhydramine. The median age of patients was 61 years. One patient had known atherosclerotic heart disease, and 2 patients had risk factors for coronary artery disease. All patients had varying degrees of evidenced high tumor burden, including lymphocytosis, elevated lactate dehydrogenase values, bulky tumor masses, and bone marrow involvement by lymphoma. All 3 patients experienced fairly typical chest pain syndromes and experienced elevations of cardiac enzymes consistent with myocardial ischemia. One patient died of an arrhythmia that deteriorated into asystole, and 2 patients recovered and underwent coronary angiography. Acute coronary syndromes can be associated with the infusion of rituximab. Patients with a history of previous coronary artery disease or risk factors for coronary artery disease should be observed closely for signs of myocardial ischemia, particularly during the initial infusion. The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively. Patients should be aware that this is a rare, albeit serious, complication of treatment with rituximab.

Cited by (34)

  • Common Vascular Toxicities of Cancer Therapies

    2019, Cardiology Clinics
    Citation Excerpt :

    Furthermore, profound coronary vasospasm as seen with 5-FU, particularly with continuous infusion (less so with bolus infusion of 5-FU and capecitabine), can lead to ST segment elevation and, if prolonged, to MI, ventricular arrhythmias, such as ventricular tachycardia and fibrillation, and even sudden cardiac death.39–41 Profound and prolonged vasospasm is considered to also underlie ACS presentations with paclitaxel, gemcitabine, rituximab, and sorafenib.42–47 The level of suspicion for an acute thrombotic event should be high in patients who present with chest pain while on cisplatin (and especially in those on concomitant therapy with additional endothelial toxic drugs, such as vinca alkaloids, bleomycin, or gemcitabine).48,49

  • Cardiac Immunomodulation

    2017, The Heart in Rheumatic, Autoimmune and Inflammatory Diseases: Pathophysiology, Clinical Aspects and Therapeutic Approaches
  • Myocardial Ischemia and Cancer Therapy

    2017, Cardio-Oncology: Principles, Prevention and Management
  • Vascular Toxicities of Cancer Therapies

    2016, Clinical Cardio-oncology
  • A systematic review of the use of rituximab as induction therapy in renal transplantation

    2015, Transplantation Reviews
    Citation Excerpt :

    6 of these deaths were due to cardiovascular events (myocardial infarction/cardiac arrest) and, given published evidence that B-lymphocytes may have an atheroprotective effect [38], the authors raise the possibility that rituximab therapy may have contributed to the excess cardiac mortality seen. There are a number of case reports and series describing cardiac morbidity related to rituximab treatment in the field of oncology [39,40] but evidence from larger studies and clinical trials has not demonstrated excess risk [41,42]. The findings of the studies which reported a high incidence of rejection using rituximab in CNI minimisation [31] and steroid avoidance [35] protocols should be interpreted with caution.

  • Myocardial infarction after rituximab infusion

    2013, Neuromuscular Disorders
    Citation Excerpt :

    Cardiac dysrhythmia is a relatively frequently (8%) reported cardiovascular side-effect in lymphoma patients treated with rituximab [3]. Myocardial infarction after rituximab infusion is extremely rare and described in only a few (n = 4) cases [4,5]. Median age of these reported patients was 60 years, all having classical cardiovascular risk factors together with a lymphoproliferative disorder (which can also be considered as a vascular risk factor).

View all citing articles on Scopus

Electronic forwarding or copying is a violation of US and International Copyright Laws.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

View full text